PK of Lidocaine/Tetracaine and PD Derived From a New Topical Formulation for Treatment of Neuropathic Pain.

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

September 23, 2024

Study Completion Date

July 28, 2025

Conditions
NeuralgiaNeuropathic PainLocal Anesthetic ComplicationLidocaine Adverse Reaction
Interventions
DRUG

Lidocaine topical

"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~1. A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~2. 10 grams will be applied every 12 hours for a period of 48 hours."

Trial Locations (1)

450881

Pontificia Universidad Catolica de Chile, Santiago

All Listed Sponsors
lead

Pontificia Universidad Catolica de Chile

OTHER